NCT06771115CompletedPhase 2
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in combination with semaglutide, or placebo in combination with semaglutide. The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period. The maximum treatment duration was 12 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 175 (actual)
- First submitted
- 8 Jan 2025
- Start date
- 7 Jan 2025
- Primary completion date
- 10 Sept 2025
- Lead sponsor
- Zomagen Biosciences Ltd.
- Diseases
- Obesity
- NCT number
- NCT06771115
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 175
- From 7 Jan 2025 to the primary completion date, 10 Sept 2025
- 14 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have any prior diagnosis of diabetes mellitus
- History or presence of clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass \[bariatric\] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity.
- Use of any medication (e.g., GLP-1 agonists), nutritional supplement, or over the counter product for weight loss within the previous 6 months or during study participation, unless administered as a part of assigned study treatment in this study.
Other illness
- Obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity
- Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.
Lab values
- Receipt of the following medications:
- Any immunosuppressive biologic or targeted therapy within 90 days prior to Day 1.
- Use of anti-inflammatory medications within 30 days prior to Day 1
- Colchicine within 30 days prior to Day 1.
- Glucose-lowering agent(s) administered for conditions other than diabetes within 90 days before screening.
Other
- Current participation (or within the last 3 months) in an organized weight reduction program.
Who the study is looking for
- Participants are male or female ≥ 18 years up to ≤ 80 years of age.
- Ability to comply with study requirements.
- BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening.
- Stable body weight (± 5%) for at least 3 months prior to screening.
- hs-CRP ≥ 2 mg/L at screening.
- Hypertension or hyperlipidemia which are known to be associated with increased risk of cardiovascular events, if present, must be controlled with stable dose/therapy.
- History of at least one self-reported unsuccessful dietary effort to lose body weight.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (14)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.